KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Intangibles (2016 - 2025)

Vertex Pharmaceuticals has reported Intangibles over the past 17 years, most recently at $424.2 million for Q4 2025.

  • Quarterly results put Intangibles at $424.2 million for Q4 2025, down 48.64% from a year ago — trailing twelve months through Dec 2025 was $424.2 million (down 48.64% YoY), and the annual figure for FY2025 was $424.2 million, down 48.64%.
  • Intangibles for Q4 2025 was $424.2 million at Vertex Pharmaceuticals, down from $429.8 million in the prior quarter.
  • Over the last five years, Intangibles for VRTX hit a ceiling of $839.9 million in Q4 2023 and a floor of $387.0 million in Q2 2022.
  • Median Intangibles over the past 5 years was $522.4 million (2022), compared with a mean of $565.3 million.
  • Biggest five-year swings in Intangibles: soared 55.97% in 2023 and later plummeted 48.64% in 2025.
  • Vertex Pharmaceuticals' Intangibles stood at $400.0 million in 2021, then soared by 50.9% to $603.6 million in 2022, then surged by 39.15% to $839.9 million in 2023, then decreased by 1.67% to $825.9 million in 2024, then plummeted by 48.64% to $424.2 million in 2025.
  • The last three reported values for Intangibles were $424.2 million (Q4 2025), $429.8 million (Q3 2025), and $435.5 million (Q2 2025) per Business Quant data.